Slika na naslovnici

42 Evaluation of pseudoprogression on immune checkpoint inhibitor therapy in gynecologic cancers

Objectives: The objective of this study is to evaluate patterns of treatment response in gynecologic cancer patients who received immune checkpoint inhibitor therapy and assess for incidence of pseudoprogression events. Methods: This IRB-approved retrospective cohort study included data from patient...

Shranjeno v:

Bibliografske podrobnosti
Main Authors:	Adeola Akapo (Author), Christine Walsh (Author)
Format:	Knjiga
Izdano:	Elsevier, 2023-06-01T00:00:00Z.
Teme:	article
Online dostop:	Connect to this object online.
Oznake:	Označite Brez oznak, prvi označite!

Podobne knjige/članki

Resistance to immune checkpoint inhibitors in colorectal cancer with deficient mismatch repair/microsatellite instability: misdiagnosis, pseudoprogression and/or tumor heterogeneity?
od: Nicola Normanno, et al.
Izdano: (2024)

Pseudoprogression in lung cancer: a case report
od: Giulia Meoni, et al.
Izdano: (2020)

Predictive biomarkers for immune checkpoint inhibitors therapy in lung cancer
od: Jie Yao, et al.
Izdano: (2024)

Concomitant medications and immune checkpoint inhibitor therapy for cancer: causation or association?
od: Nadiya Hussain, et al.
Izdano: (2021)

Resistance to immune checkpoint inhibitors in gastric cancer
od: Kai Liu, et al.
Izdano: (2023)

An overview of immune checkpoint inhibitors in breast cancer
od: Federica Miglietta, et al.
Izdano: (2020)

Hepatobiliary complications of immune checkpoint inhibitors in cancer
od: Donna Zhuang, et al.
Izdano: (2024)

Drug therapy for myocarditis induced by immune checkpoint inhibitors
od: Yihao Wu, et al.
Izdano: (2023)

Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy
od: Matthew D Biniakewitz, et al.
Izdano: (2021)

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
od: Rilan Bai, et al.
Izdano: (2020)

Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
od: Pan Shen, et al.
Izdano: (2021)

How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy
od: Paolo Spallarossa, et al.
Izdano: (2020)

Immune Checkpoint Inhibitors New Insights and Recent Progress
Izdano: (2023)

Predictors of response to immune checkpoint inhibition in a real world gynecologic cancer population
od: Michelle L. Kuznicki, et al.
Izdano: (2020)

A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
od: Yukinobu Watanabe MD, PhD, et al.
Izdano: (2021)

The gut microbiota and immune checkpoint inhibitors
od: Audrey Humphries, et al.
Izdano: (2018)

Cardiovascular complications of immune checkpoint inhibitors
od: A. A. Kulievа, et al.
Izdano: (2020)

Immune Checkpoint Inhibitors and Lupus Erythematosus
od: Hans Vitzthum von Eckstaedt, et al.
Izdano: (2024)

Pseudoprogression of cutaneous squamous cell carcinoma invading the super vermillion border following programmed death‐1 inhibitor monotherapy
od: Sach Thakker, et al.
Izdano: (2024)

Immune checkpoint inhibitors in esophageal cancer: Clinical development and perspectives
od: Yusuke Nagata, et al.
Izdano: (2022)

Application of immune checkpoint inhibitors for resectable gastric/gastroesophageal cancer
od: Feizhi Lin, et al.
Izdano: (2024)

Immune checkpoint inhibitors and prostate cancer: a new frontier?
od: Alessandra Modena, et al.
Izdano: (2016)

Immune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate?
od: Tang-Her Jaing, et al.
Izdano: (2024)

Cardiotoxicity mechanisms of antitumor therapy with immune checkpoint inhibitors: new achievements
od: L. D. Khidirova, et al.
Izdano: (2024)

Drug Repurposing to Circumvent Immune Checkpoint Inhibitor Resistance in Cancer Immunotherapy
od: Kenneth K. W. To, et al.
Izdano: (2023)

Cost-effectiveness of immune checkpoint inhibitors in treating metastatic urothelial cancer
od: Li-Yu Yang, et al.
Izdano: (2024)

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
od: Gopalakrishnan D, et al.
Izdano: (2018)

Immune checkpoint inhibitors: An innovation in immunotherapy for the treatment and management of patients with cancer
od: Jennifer Dine, et al.
Izdano: (2017)

Immune checkpoint inhibitor-associated sarcoidosis reaction
od: Parisa Keshtgar, et al.
Izdano: (2023)

Skin Manifestation Induced by Immune Checkpoint Inhibitors
od: Yamamoto T
Izdano: (2022)

Immune Checkpoint Inhibitors in Melanoma: Review and Update
od: Eugénia Matos Pires, et al.
Izdano: (2018)

Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
od: Xi Chen, et al.
Izdano: (2022)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
od: Katarina Hradska, et al.
Izdano: (2021)

Clinical Insights Into Novel Immune Checkpoint Inhibitors
od: Jii Bum Lee, et al.
Izdano: (2021)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
od: Ji Won Han, et al.
Izdano: (2021)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: An Overview
od: Diederick J. van Doorn, et al.
Izdano: (2020)

Obesity paradox in patients with non‐small cell lung cancer undergoing immune checkpoint inhibitor therapy
od: Ji Hyun Lee, et al.
Izdano: (2023)

Immune checkpoint inhibitors in cancer therapy: Review of orofacial adverse events and role of the oral healthcare provider
od: Brittany A. Klein, et al.
Izdano: (2022)

Effects of PPIs use on clinical outcomes of urothelial cancer patients receiving immune checkpoint inhibitor therapy
od: Lilong Zhang, et al.
Izdano: (2022)

Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis
od: Yu Lu, et al.
Izdano: (2023)